Breast Neoplasm Female, Cancer, Breast, Thermography
Conditions
Brief summary
This study is designed to evaluate the Sentinel BreastScan II as well as the analysis of data by Therma-Scan.
Detailed description
FirstSense Medical, LLC is a medical device company which has developed a breast cancer screening device, the Sentinel BreastScan II \[SBS II\]. This radiation free device is being developed to produce data which will be analyzed by Therma-Scan Reference Laboratory. Dr. Hoekstra, CEO of Therma-Scan, is the author of a published paper based on breast thermal data with a reported 95% sensitivity and 91% specificity. The SBS II examination will take approximately 7 minutes. This study is designed to evaluate the Sentinel BreastScan II as well as the analysis of data by Therma-Scan. SBS II thermal breast data is an adjunctive aid to standard breast imaging. Currently, mammography is one of the standards of care in screening for visible signs of breast cancer. Breast thermology is the analysis of the heat signature data from an examined breast. All study costs will be incurred by the sponsor. Study subjects will incur no cost to participate. All scientific data revealed in this protocol will be used for the specific objectives of the study. The SBS II is a non-significant risk device. There is no contact with the subject during the entire procedure.
Interventions
DEVICESentinel BreastScan II
The SBS II will automate the recording of thermal data used in the Therma-Scan manual thermology protocol by utilizing a thermal camera sensitive to changes in breast temperature. The SBS II system uses a very sensitive thermography camera that detects and visually displays heat patterns that naturally emanate from the breast. SBS II captures this data digitally for subsequent analysis by Therma-Scan.
Sponsors
University of Toledo Health Science Campus
First Sense Medical, LLC
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Male or Female, over the age of 18 years of age. * Asymptomatic women or women who are being screened for breast abnormality. * Women scheduled for a mammogram or women who have had a mammogram and are given 3 days to wait in between their mammogram and scheduled biopsy and FS/TS system. * Not pregnant or breast feeding. * Signed Informed consent.
Exclusion criteria
* Subject does not meet inclusion criteria, noted above. * Use of 100 mg or more of niacin by tablet or niacin patch within the last 24 hours. * Use of nitroglycerin within the last 24 hours. * Subject experienced a fever of 102°F or higher within thirty-six (36) hours of the study. * Subject must not have had a mammogram, breast ultrasound, or breast exam within the last 72 hours prior to the SBS II.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Measure protocol accuracy | Through study completion, an average of 4 years. | To measure the sensitivity and specificity of thermographic analysis based on the Marseilles analytic protocol \[ Th 1 thru 5 \] to biopsy results predicated on standard breast imaging criteria \[ BIRADS analytical protocol, B1 thru B5 \]. The resultant BIRADS score and biopsy pathological results will be compared to thermographic analysis \[ Th1 thru 5 \] for each subject. 50 subjects undergoing both thermography and standard breast imaging leading to biopsy \[ BIRADS 3 thru 5 \] will then be compared by measuring the results of each, BIRADS for standard breast imaging v the Marseilles Th system used in thermographic analysis, for concordance or discordance of findings as measured on final pathological analysis. This analysis will be performed for each subsequent 50 patient cohort undergoing standard mammographic/ultrasound breast imaging analysis. |
Countries
United States
Outcome results
None listed